Opinion|Videos|July 29, 2024
Biosimilars in the Commercial Sector
Dr. Cannon discusses payers and PBMs making decisions about biosimilars in the commercial sector.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How are payers and PBMs making decisions about biosimilars in the commercial sector?
a. What key factors are considered for formulary decisions in the commercial sector?
b. Discussion points: What makes the commercial sector unique, employer/payer payment models.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
2
Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care
3
GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis
4
MDS/MPN Response Criteria Tied to Survival
5